1954 Les Laboratoires Servier founded in Orleans, France 1955 Launched first two products into hypertensive and diabetic markets 1960 First research centre established in Suresnes, Paris 1962 First chemical production centre established in Bolbec, France 1963 Second international subsidiary opened in London 1979 Servier Laboratories established in Australia 1995 Acquired 51% share holding in EGIS Pharmaceuticals in Hungary 1997 Acquired Anpharm in Poland 1999 International Centre for Therapeutic research established in Australia-The first outside of Europe 2000 Production plant built in China 2002 Servier Laboratories awarded prestigious Prix Galien for ‘quality and dynamism of its therapeutic research’ 2004 Servier celebrates 25 years in Australia with a turnover of $100 million 2007 Servier Australia launched Protos, a 'first in class' treatment in osteoporosis
About Servier Australia:
Servier Australia is the local subsidiary of Servier, a leading French research-based pharmaceutical entity, specialising in ethical pharmaceuticals. Employing over 200 people in Australia, its headquarters are in Hawthorn, Melbourne. In 2009 Servier Australia had an annual turnover of $107 million.
Servier Laboratories Limited comprises two principal divisions:
Clinical Research The management of phase l, ll, lll and lV clinical trials in collaboration with research-based hospitals and general practices throughout Australia.
Sales and Marketing Sales and Marketing deliver Servier’s portfolio of ethical pharmaceutical products to primary and secondary healthcare professionals
In addition to a team of representatives throughout Australia, to support the operational activities of the above divisions, there is naturally a complete range of professional support functions that include the following: Training, Medical Information (Marketing), Regulatory Affairs, Human Resources, Finance, Information Services, Strategic Coordination, External and Government Relations and Medical Affairs.
Servier Australia offers a range of products in a number of medical areas: cardiovascular disease, especially hypertension and cardiac disease, diabetes and more recently osteoporosis.
History of Servier In Australia
In just over 20 years, turnover has increased from $1 million in 1984 to $107 million for 2009. The number of people employed has risen steadily. The Sales force has grown from 6 representatives in 1984 spread across all Australian regions to in excess of 120 representatives today, but has maintained its reputation throughout this time as being amongst one of the best trained, most professional and most productive in Australia.
Servier’s activities in Australia commenced in 1979 with the launch of the anti-diabetic agent- Diamicron
Pivotal development work for the group’s flagship product Coversyl, which led to more than 30 publications from Australian researchers prior to marketing approval, culminated with the launch of Coversyl 2mg and 4mg in 1992.
In 1999 The International Centre for Therapeutic Research was established in Australia- The first outside of Europe and now has a staff in excess of 30 involved in phase l,ll and lll clinical research.
By January 1999 the company had outgrown it’s head office of 15 years and moved to it’s new purpose built office in Hawthorn, Melbourne, which saw the divisions of Sales/Marketing and Research all housed under the one roof.
Coversyl 8mg was launched in February 2004 and already contributes 21% of the Company annual turnover.
Coralan, a new treatment for chronic stable angina was registered in November 2006.
In April 2007, Protos, a new treatment for post menopausal osteoporosis was listed on the PBS.
Our Pipeline
Servier regularly invests more than 25% of its annual turnover into research and development and spent more than 530 million euros alone on the development of PROTOS, its innovative new treatment for osteoporosis.
Servier’s R&D pipeline is extremely healthy having the potential to submit one product for licence every year for the next 8 to 10 years, with Servier Australia and the whole Servier Research Group set for dramatic growth over this period. From a product portfolio focused on Cardiovascular, Diabetes and Osteoporosis, Servier plans to not only have some innovative new products in these therapeutic fields, but by 2014 plans to promote new and existing products for Type 2 diabetes, hypertension, prevention of cardiovascular events, depression and mild cognitive impairment.
Servier Internationally
In the short space of fifty years, Servier has developed in stature from a family-owned, provincial pharmacy employing nine people to a multi-national operation with over 20,000 employees worldwide, including nearly 3,000 in R&D. Despite its significant growth in recent years, the Company is still privately owned and is passionately and permanently committed to remaining independent.
IN FRANCE success has been spectacular. Currently the second largest French pharmaceutical company worldwide, it is also the largest privately owned and the second largest exporter of pharmaceutical products. In people terms, the work force now totals some 5,000 employees, of whom one in four is actively engaged in the research and development of new compounds.
INTERNATIONALLY the Company's expansion has been equally impressive. Currently established in 140 countries, it has achieved consistently high growth especially throughout the last decade. The reason for this success is three-fold: firstly, one of the world's highest ratios of investment in research and development; secondly, an enviable reputation for product innovation; thirdly, the motivation, commitment and professionalism of the Company’s personnel are second to none.
More than 25% of turnover is invested in R&D
Nearly 3,000 employees engaged in R&D
Principle areas of therapeutic research: - Cardiovascular diseases - Central nervous system and psychiatry - Oncology - Diabetes and metabolism - Rheumatology
In 1995, Servier acquired a 51% shareholding in EGIS, the leading Hungarian pharmaceutical company. Additionally, in 1997, Servier, together with its Hungarian subsidiary EGIS, took a majority holding in the Polish pharmaceutical company Anpharm.
print
About Servier Australia:
History of Servier In Australia 
Servier regularly invests more than 25% of its annual turnover into research and development and spent more than 530 million euros alone on the development of PROTOS, its innovative new treatment for osteoporosis.